CN110612300B - 制备乙型肝炎核心蛋白调节剂的方法 - Google Patents

制备乙型肝炎核心蛋白调节剂的方法 Download PDF

Info

Publication number
CN110612300B
CN110612300B CN201880030078.4A CN201880030078A CN110612300B CN 110612300 B CN110612300 B CN 110612300B CN 201880030078 A CN201880030078 A CN 201880030078A CN 110612300 B CN110612300 B CN 110612300B
Authority
CN
China
Prior art keywords
compound
formula
hours
mmol
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880030078.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110612300A (zh
Inventor
L.李
L.D.阿诺德
S.雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assembly Biosciences Inc
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of CN110612300A publication Critical patent/CN110612300A/zh
Application granted granted Critical
Publication of CN110612300B publication Critical patent/CN110612300B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880030078.4A 2017-03-13 2018-03-13 制备乙型肝炎核心蛋白调节剂的方法 Expired - Fee Related CN110612300B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762470560P 2017-03-13 2017-03-13
US62/470,560 2017-03-13
PCT/US2018/022100 WO2018169907A1 (en) 2017-03-13 2018-03-13 Process for making hepatitis b core protein modulators

Publications (2)

Publication Number Publication Date
CN110612300A CN110612300A (zh) 2019-12-24
CN110612300B true CN110612300B (zh) 2023-10-20

Family

ID=61768549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030078.4A Expired - Fee Related CN110612300B (zh) 2017-03-13 2018-03-13 制备乙型肝炎核心蛋白调节剂的方法

Country Status (9)

Country Link
US (2) US11040965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596070A1 (cg-RX-API-DMAC7.html)
JP (1) JP7179751B2 (cg-RX-API-DMAC7.html)
KR (1) KR102575605B1 (cg-RX-API-DMAC7.html)
CN (1) CN110612300B (cg-RX-API-DMAC7.html)
AU (1) AU2018236188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3056696A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908475RA (cg-RX-API-DMAC7.html)
WO (1) WO2018169907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
BR112019018230A2 (pt) 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização
SG11202112590WA (en) * 2019-05-24 2021-12-30 Assembly Biosciences Inc Pharmaceutical compositions for the treatment of hbv
CN111333513B (zh) * 2020-04-17 2021-08-27 江苏恒沛药物科技有限公司 一种2,4-二氟-3-硝基苯甲酸的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104803880A (zh) * 2014-01-23 2015-07-29 广州喜鹊医药有限公司 一种具有神经保护作用的化合物及其制备方法和应用
CN106413402A (zh) * 2014-03-13 2017-02-15 美国印第安纳大学研究和技术公司 乙型肝炎核心蛋白变构调节剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (ja) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd ジベンゾオキサゼピン誘導体
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
EP1937677A1 (en) 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (ja) 2006-03-10 2008-02-06 健治 吉田 情報処理装置への入力処理システム
WO2008036139A2 (en) 2006-06-07 2008-03-27 The Regents Of The University Of California Inhibitors of mshc and homologs thereof, and methods of identifying same
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
BRPI0916540B8 (pt) 2008-07-23 2021-05-25 Us Health inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
RU2519546C1 (ru) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2015017412A1 (en) 2013-07-29 2015-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
KR20170018898A (ko) 2014-06-10 2017-02-20 바스프 에스이 살진균제로서의 치환된 [1,2,4]트리아졸 및 이미다졸 화합물
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
AU2017326356A1 (en) * 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104803880A (zh) * 2014-01-23 2015-07-29 广州喜鹊医药有限公司 一种具有神经保护作用的化合物及其制备方法和应用
CN106413402A (zh) * 2014-03-13 2017-02-15 美国印第安纳大学研究和技术公司 乙型肝炎核心蛋白变构调节剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An efficient method for the oxidation of sulfides to sulfones;Weiguo Su;《Tetrahedron Letters》;19940711;第4956页表1 *
Synthesis of substituted diphenyl sulfones and their structure–activity relationship with the antagonism of 5-HT6 receptors;Alexandre Ivachtchenko et al;《Bioorganic & Medicinal Chemistry》;20130601;第4616页图表1 *

Also Published As

Publication number Publication date
KR102575605B1 (ko) 2023-09-05
CA3056696A1 (en) 2019-09-20
US11040965B2 (en) 2021-06-22
AU2018236188B2 (en) 2022-01-27
EP3596070A1 (en) 2020-01-22
CN110612300A (zh) 2019-12-24
SG11201908475RA (en) 2019-10-30
KR20190128675A (ko) 2019-11-18
US20200002325A1 (en) 2020-01-02
WO2018169907A1 (en) 2018-09-20
JP7179751B2 (ja) 2022-11-29
US20210380577A1 (en) 2021-12-09
JP2020510059A (ja) 2020-04-02
AU2018236188A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP6602311B2 (ja) Ｂ型肝炎コアタンパク質アロステリックモジュレーター
TWI721016B (zh) B型肝炎核心蛋白質調節劑
JP4234344B2 (ja) スルホンアミド含有複素環化合物
US20210380577A1 (en) Process for making hepatitis b core protein modulators
CN110621672A (zh) 环状磺酰胺化合物及其使用方法
CA3079833A1 (en) Bridged bicyclic compounds as farnesoid x receptor modulators
CN109937201A (zh) 乙型肝炎核心蛋白调节剂
JPWO2006008874A1 (ja) アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤
JP5022040B2 (ja) Ｌｘｒモジュレーターとしての化合物および組成物
CN115433256A (zh) 一种氮杂双环[3.1.0]己烷衍生物及其制备方法和用途
EA039771B1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
NZ723972B2 (en) Hepatitis b core protein allosteric modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231020